search
Back to results

Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients

Primary Purpose

Knee Osteoarthritis

Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
Vitamin D3 (cholecalciferol)
Sponsored by
University of Zurich
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Knee Osteoarthritis

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Unilateral knee replacement due to knee osteoarthritis
  • Age 60+ years
  • German language skills
  • community dwelling

Exclusion Criteria:

  • Bi-lateral knee replacement or hip replacement planned in the trial period, or in the previous 6 months
  • Chronic steroid intake
  • Serum calcium corrected for serum albumin > 2.6 mmol/l
  • GFR < 30 ml/min
  • Severe visual or hearing impairment
  • Inflammatory arthritis
  • Malabsorption
  • High alcohol intake
  • Sarcoidosis, primary hyperparathyroidism
  • History of kidney stones, lymphoma
  • Chemotherapy for cancer in the previous 12 months
  • Hemiplegia
  • Morbus Parkinson
  • Unable to walk 3 meters prior to surgery
  • Bisphosphonate, parathyroid hormone , fluoride or calcitonine therapy in the last 6 months
  • Zolendronate in the last year
  • M. Paget (Ostitis deformans)
  • Vitamin D3 intake more than 800IU/d over more than 1 month
  • stay on a sunny location for more than 6 weeks per year
  • heart failure

Sites / Locations

  • University Hospital Zurich, Centre on Aging and Mobility

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

1: 2000 IU D3/day

2: 800 IU D3 / day

Arm Description

2000 IU vitamin D3 taken orally each day for 2 years

800 IU vitamin D3 taken orally each day for 2 years

Outcomes

Primary Outcome Measures

pain and function of the operated and non-operated knee
rate of falls

Secondary Outcome Measures

strength, balance, function, physical activity
bone density, bone quality
body composition
blood pressure
number of teeth
cost, health care utilization
facial skin keratosis (number and size)
cognitive function
depression, mental health
fasting blood glucose - insulin levels
Number of upper respiratory infections and number of any infections
bone metabolism
radiographic progression of the non-operated knee
general pain
Quality of life

Full Information

First Posted
January 10, 2008
Last Updated
October 27, 2014
Sponsor
University of Zurich
Collaborators
Harvard School of Public Health (HSPH), Tufts University, Boston University
search

1. Study Identification

Unique Protocol Identification Number
NCT00599807
Brief Title
Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients
Official Title
Role of Vitamin D in Secondary Prevention of Knee Osteoarthritis: A Double-blind Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
March 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Zurich
Collaborators
Harvard School of Public Health (HSPH), Tufts University, Boston University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a 2-year double-blind randomized controlled trial in 287 community-dwelling individuals age 60 years or older undergoing uni-lateral total knee replacement due to severe OA of the knee.We compare an oral dose of 2000 IU vitamin D3 per day to 800 IU. The primary endpoints are pain and disability related to rehabilitation of the operated knee,and related to the expected high prevalence of OA in the contra-lateral knee. Secondary endpoints are change in 25(OH)D levels, muscle strength, balance, lower extremity function, the rate of falls, bone density and bone quality, bone metabolism, general pain, fall-related fractures, body composition, blood-pressure, major cardiovascular events, blood glucose-insulin levels, executive cognitive function, rate of upper respiratory tract infections / all infections, tooth loss, dental health, health care utilization, number and size of facial skin keratosis, and radiographic progression of the non-operated knee. Pain and disability will be assessed by the pain and function subscales of the Western Ontario- McMaster Universities Osteoarthritis Index (WOMAC). Randomization will be stratified by WOMAC function prior to surgery, radiological evidence for OA in the contra-lateral knee, and hospital. Clinical visits will take place at baseline (6-8 weeks after TKR), at 6, 12, 18 and 24 months of treatment. In addition, all individuals will receive a phone call every 2 month to assess adverse outcomes and compliance to treatment, supported by a hotline for immediate report of adverse events. Statistical power: We expect more than 80% power with 200 participants completing their 24 month follow-up, and 260 participants completing their 12 month follow-up. This is a trial with medicinal product.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Osteoarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
273 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1: 2000 IU D3/day
Arm Type
Active Comparator
Arm Description
2000 IU vitamin D3 taken orally each day for 2 years
Arm Title
2: 800 IU D3 / day
Arm Type
Active Comparator
Arm Description
800 IU vitamin D3 taken orally each day for 2 years
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D3 (cholecalciferol)
Intervention Description
the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)
Primary Outcome Measure Information:
Title
pain and function of the operated and non-operated knee
Time Frame
0, 6,12,18, 24 months
Title
rate of falls
Time Frame
0, 24 months
Secondary Outcome Measure Information:
Title
strength, balance, function, physical activity
Time Frame
0,6,12,18,24 months
Title
bone density, bone quality
Time Frame
0, 24 months
Title
body composition
Time Frame
0, 24 months
Title
blood pressure
Time Frame
0,12,24 months
Title
number of teeth
Time Frame
0, 24 months
Title
cost, health care utilization
Time Frame
0,6,12,18,24 months
Title
facial skin keratosis (number and size)
Time Frame
0, 24 months
Title
cognitive function
Time Frame
0, 24 months
Title
depression, mental health
Time Frame
0,12,24 months
Title
fasting blood glucose - insulin levels
Time Frame
0,12,24
Title
Number of upper respiratory infections and number of any infections
Time Frame
0, 6,12,28,24
Title
bone metabolism
Time Frame
0,6,12,18,24
Title
radiographic progression of the non-operated knee
Time Frame
0, 24 months
Title
general pain
Time Frame
0,6,12,18,24 months
Title
Quality of life
Time Frame
0,6,12,18,24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Unilateral knee replacement due to knee osteoarthritis Age 60+ years German language skills community dwelling Exclusion Criteria: Bi-lateral knee replacement or hip replacement planned in the trial period, or in the previous 6 months Chronic steroid intake Serum calcium corrected for serum albumin > 2.6 mmol/l GFR < 30 ml/min Severe visual or hearing impairment Inflammatory arthritis Malabsorption High alcohol intake Sarcoidosis, primary hyperparathyroidism History of kidney stones, lymphoma Chemotherapy for cancer in the previous 12 months Hemiplegia Morbus Parkinson Unable to walk 3 meters prior to surgery Bisphosphonate, parathyroid hormone , fluoride or calcitonine therapy in the last 6 months Zolendronate in the last year M. Paget (Ostitis deformans) Vitamin D3 intake more than 800IU/d over more than 1 month stay on a sunny location for more than 6 weeks per year heart failure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Heike Bischoff-Ferrari, MD, MPH
Organizational Affiliation
University Hospital Zurich, Centre on Aging and Mobility
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Zurich, Centre on Aging and Mobility
City
Zurich
State/Province
ZH
ZIP/Postal Code
8091
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
32542307
Citation
Abderhalden LA, Meyer S, Dawson-Hughes B, Orav EJ, Meyer U, de Godoi Rezende Costa Molino C, Theiler R, Stahelin HB, Ruschitzka F, Egli A, Forman JP, Willett WC, Bischoff-Ferrari HA. Effect of daily 2000 IU versus 800 IU vitamin D on blood pressure among adults age 60 years and older: a randomized clinical trial. Am J Clin Nutr. 2020 Sep 1;112(3):527-537. doi: 10.1093/ajcn/nqaa145.
Results Reference
derived
PubMed Identifier
31557423
Citation
Freystaetter G, Fischer K, Orav EJ, Egli A, Theiler R, Munzer T, Felson DT, Bischoff-Ferrari HA. Total Serum Testosterone and Western Ontario and McMaster Universities Osteoarthritis Index Pain and Function Among Older Men and Women With Severe Knee Osteoarthritis. Arthritis Care Res (Hoboken). 2020 Nov;72(11):1511-1518. doi: 10.1002/acr.24074.
Results Reference
derived
PubMed Identifier
31152541
Citation
Schietzel S, Fischer K, Brugger P, Orav EJ, Renerts K, Gagesch M, Freystaetter G, Stahelin HB, Egli A, Bischoff-Ferrari HA. Effect of 2000 IU compared with 800 IU vitamin D on cognitive performance among adults age 60 years and older: a randomized controlled trial. Am J Clin Nutr. 2019 Jul 1;110(1):246-253. doi: 10.1093/ajcn/nqz081.
Results Reference
derived

Learn more about this trial

Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients

We'll reach out to this number within 24 hrs